Search Within

Pamela R Drullinsky

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (11)
  2. Journal Article (3)
Groups
  1. Breast Medicine Service (14)
  2. Department of Medicine (14)
  3. GSK Faculty (14)
  4. Human Oncology and Pathogenesis Program (14)
  5. Solid Tumor Oncology Division (14)
  6. Biostatistics Service (13)

More Groups

People
  1. Sarat Chandarlapaty (8)
  2. Shanu Modi (8)
  3. Clifford Hudis (7)
  4. Sujata Patil (7)
  5. Chau Dang (5)
  6. Ai Ni (4)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2017 (2)
  4. 2016 (3)
  5. 2015 (1)
  6. 2014 (1)

More Years

Publications
  1. Cancer Research (4)
  2. Blood (3)
  3. Journal of Clinical Oncology (2)
  4. Breast Cancer Research and Treatment (1)
  5. Clinical Breast Cancer (1)
  6. Hematological Oncology (1)

More Publications

Publishers
  1. American Association for Cancer Research (4)
  2. American Society of Hematology (3)
  3. American Society of Clinical Oncology (2)
  4. Elsevier Inc. (2)
  5. Elsevier Science, Inc. (1)
  6. Springer (1)

More Publishers

Results (14)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer
    Meeting Abstract

    Datko, F.; D'Andrea, G.; Dickler, M.; Theodoulou, M.; Goldfarb, S.; Lake, D.; Fornier, M.; Modi, S.; Sklarin, N.; Comen, E.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+ metastatic breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Modi, S.; Drullinsky, P.; Syldor, A.; Patil, S.; Seidman, A.; Norton, L.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Seidman, A. D.; Modi, S.; Dickler, M.; Drullinsky, P.; Syldor, A.; Sujata, P.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • A phase II trial of ganetespib: Efficacy and safety in patients (pts) with metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Drullinsky, P.; Sugarman, S.; Wasserheit-Leiblich, C.; Moynahan, M. E.; D'Andrea, G.; Haque, S.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save